Starpharma(OTC) SPHRY

Market Cap$255.70M

Since IPO (2005)-14%

5 Year-45%

1 Year+557%

1 Month+12%

$5.55

+3.55%

+0.19Today

Starpharma last closing stock price
Metric	Price	Date
Last close	USD 5.55	2026-09-18

Starpharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+9.9%	USD 5.05	2026-09-11
1 month	+12.12%	USD 4.95	2026-08-19
3 month	+11%	USD 5.00	2026-06-18
Year to date	+128.87%	USD 2.43	2025-12-30
1 year	+556.99%	USD 0.84	2025-09-18
3 year	+397.76%	USD 1.12	2023-09-19
5 year	-45.32%	USD 10.15	2021-09-17
Since inception	-14.01%	USD 6.23	2005-01-20

Starpharma Financials at a Glance

Market Cap

$255.70M

Revenue (TTM)

A$16.01M

Net Income (TTM)

-A$15.31M

EPS (TTM)

-$0.12

P/E Ratio

-43.65

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$5.55

Volume

3,100

Open

$5.50

Price

$5.55

Volume

3,100

Open

$5.50

Previous Close

$5.55

Daily Range

$5.50 - $5.56

52-Week Range

$0.84 - $5.82

Estimated Earnings Date

Aug 26, 2026

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$5.55

Volume

3,100

Open

$5.50

Previous Close

$5.55

Daily Range

$5.50 - $5.56

52-Week Range

$0.84 - $5.82

Estimated Earnings Date

Aug 26, 2026

SPHRY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Starpharma

Starpharma Holdings Limited is an Australian biopharmaceutical company focused on advancing proprietary dendrimer technology across various sectors, including pharmaceuticals and life sciences. The company offers innovative products such as VivaGel, an effective treatment for bacterial vaginosis, and VIRALEZE, an antiviral nasal spray.

Products and Services

VivaGel for managing bacterial vaginosis
VIRALEZE antiviral nasal spray for respiratory infections
DEP dendrimer drug delivery system with multiple oncology candidates

Growth Outlook

Strong pipeline with several oncology candidates in Phase II trials
Recent revenue growth of 6.2% quarter-over-quarter
Increased cash reserves of AUD 18.2 million as of December 2025

Financial Highlights

Recent quarterly revenue of AUD 10.6 million, a significant increase
Gross profit margin of 92.7% in the latest quarter
Current ratio of 5.26, indicating strong liquidity

Starpharma Holdings Limited is positioned to leverage its innovative technology and product offerings in the growing biopharmaceutical market. The company's focus on dendrimer technology provides a unique advantage in drug delivery systems, particularly in oncology. Recent financial performance indicates a positive trend, with notable revenue growth and a strong gross profit margin. The substantial cash reserves enhance the company's ability to fund ongoing research and development, supporting its ambitious growth strategy. As Starpharma continues to advance its clinical programs, it remains a compelling entity within the biotechnology sector.

AI Generated • Aug 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Cheryl Maley, MBA

Website

www.starpharma.com

Headquarters

Abbotsford, VIC 3067, AU

SPHRY Financials

Key Financial Metrics (TTM)

Gross Margin

86.26%

Operating Margin

-159.60%

Net Income Margin

-61.95%

Return on Equity

-42.35%

Return on Capital

-129.88%

Return on Assets

-39.25%

Earnings Yield

-2.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$255.70M

Shares Outstanding

47.71M

Volume

3.10K

Avg. Volume

681.46

Financials (TTM)

Gross Profit

A$7.22M

Operating Income

-A$36.26M

EBITDA

-A$26.50M

Operating Cash Flow

-A$6.49M

Capital Expenditure

-A$320.54K

Free Cash Flow

-A$6.82M

Cash & ST Invst.

A$11.02M

Total Debt

A$707.04K

Starpharma Performance Analysis

Starpharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	AUD 1,977,079	-41.8%
2024	2024-06-30	AUD 5,432,404	174.8%
2025	2025-06-30	AUD 3,181,163	-41.4%
2026	2026-06-30	AUD 8,165,356	156.7%

Starpharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	40.2%
Q4	2025-06-30	-29.5%
Q2	2025-12-31	521.3%
Q4	2026-06-30	-88.4%

Starpharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	AUD -0.25	-10.7%
2024	2024-06-30	AUD -0.13	-49.4%
2025	2025-06-30	AUD -0.15	19.3%
2026	2026-06-30	AUD -0.12	-22.3%

Starpharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	24.9%
Q4	2025-06-30	57.7%
Q2	2025-12-31	158.2%
Q4	2026-06-30	-731.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

A$1.24M

-28.6%

Gross Profit

A$360.01K

+110.3%

Gross Margin

29.15%

N/A

Market Cap

$255.70M

N/A

Market Cap/Employee

$5.11M

N/A

Employees

N/A

Net Income

-A$8.96M

-25.6%

EBITDA

-A$15.54M

-122.5%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

A$11.02M

-52.8%

Total Debt

A$707.04K

-80.0%

Accounts Receivable

A$4.39M

-30.8%

Inventory

A$1.66M

-31.3%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$707.04K

-55.0%

Return on Assets

-39.25%

N/A

Return on Invested Capital

-1.39%

N/A

Free Cash Flow

-A$7.02M

+23.3%

Operating Cash Flow

-A$6.95M

+23.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BIOYFBioSyent Inc.

BIOYFBioSyent Inc.$11.25-1.32%

PRNAFAlterity Therapeutics Limited

PRNAFAlterity Therapeutics Limited$0.40+0.00%

BSEMBioStem Technologies, Inc.

BSEMBioStem Technologies, Inc.$4.74+8.72%

IUGNFImugene Limited

IUGNFImugene Limited$0.05+12.50%

PHYOFIXICO plc

PHYOFIXICO plc$0.07+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$152.71-1.36%

NVDANvidia

NVDANvidia$222.27+1.34%

AGNCAGNC Investment Corp.

AGNCAGNC Investment Corp.$9.87-0.40%

INTCIntel

INTCIntel$108.60-0.18%

NOKNokia

NOKNokia$10.68+0.76%

TTDThe Trade Desk

TTDThe Trade Desk$13.92-2.38%

NFLXNetflix

NFLXNetflix$71.79-4.67%

Questions About SPHRY

What is the current price of Starpharma?

Starpharma is trading at $5.55 per share.

What is the 52-week range for Starpharma?

Over the past 52 weeks, Starpharma has traded between $0.84 and $5.82.

How much debt does Starpharma have?

As of the most recent reporting period, Starpharma reported total debt of A$489.81K.

How much cash does Starpharma have on hand?

Starpharma reported A$7.63M in cash and cash equivalents in its most recent financial results.

What is Starpharma’s dividend yield?

Starpharma does not currently have a dividend yield.

Starpharma(OTC) SPHRY

Starpharma Financials at a Glance

SPHRY News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Starpharma

SPHRY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Starpharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SPHRY

What is the current price of Starpharma?

What is the 52-week range for Starpharma?

How much debt does Starpharma have?

How much cash does Starpharma have on hand?

What is Starpharma’s dividend yield?

Premium Investing Services